Skip to main content

Table 3 Impact of peer support on virologic failure at months 6, 12, 18 and 24 (n = 640)

From: Impact of peer support on virologic failure in HIV-infected patients on antiretroviral therapy - a cluster randomized controlled trial in Vietnam

Months Intervention group
(n = 332)
Control group
(n = 308)
RR 95% CI P-Value**
Virologic failure risk (95% CI) Virologic failure risk (95% CI) Virologic failure risk (95% CI) Cumulative virologic failure risk (95% CI)
6 m 11
(3.3%, 1.4–5.2%)
11
(3.3%, 1.4–5.2%)
11
(3.5%, 1.5–5.6%)
11
(3.5%, 1.5–5.6%)
0.9 0.4 < RR < 2.1 0.86
12 m 6
(1.8%, 0.3–3.2%)
17
(5.1%, 2.7–7.5%)
9 (2.9%, 1–4.8%) 20
(6.5%, 3.7–9.3)
0.6 0.2 < RR < 1.7 0.35
18 m 4
(1.2%, 0.1–2.3%)
21
(6.3%, 3.6–9%)
1 (0.3%, 0–1%) 21
(6.8%, 3.9–9.7%)
3.7 0.4 < RR < 33 0.21
24 m 2 (0.6%, 0–1.4%) 23
(6.9%, 4.1–9.7%)
2 (0.6%, 0–1.5%) 23
(7.5%, 4.4–10.5%)
0.9 0.1 < RR < 6.5 0.94
  1. CI Confidence Interval, RR Relative Risk
  2. **Chi-square test